November 1, 2015
View Full PaperMicroRNA Expression Changes after Atrial Fibrillation Catheter Ablation
Key Result
MicroRNAs may serve as biomarkers for atrial fibrillation alterations and could potentially be used as targeted therapy to prevent cardiac remodeling after catheter ablation.
Structured PICO
P
Population
Patients with atrial fibrillation undergoing catheter ablation (general discussion)
I
Intervention
microRNA target therapy (upregulation by adenovirus transfection and/or downregulation by antagomiR) in conjunction with catheter ablation
MicroRNAs have potential as biomarkers for predicting response to AF catheter ablation and as therapeutic targets to prevent electrical and fibrotic remodeling.
Abstract
Atrial fibrillation (AF) is most common arrhythmia in general population, with increasing trend in mortality and morbidity. Electrophysiological and structural abnormalities, promoting abnormal impulse formation and propagation, lead to this disease. AF catheter ablation is related to a not small percentage of nonresponder patients. microRNAs (miRs) have been used as AF fibrotic and electrical alterations biomarkers. miRs may differentiate responders patients to ablative approach. Selective miR target therapy, as upregulation by adenovirus transfection and/or miR downregulation by antagomiR, may be used to treat AF patients. Catheter ablation of triggering electrical pulmonary veins activity or fibrotic areas defragmentation may be upgraded by miR therapy to prevent cardiac electrical and fibrotic remodeling after AF ablation.